UA61902C2 - Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition - Google Patents

Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition Download PDF

Info

Publication number
UA61902C2
UA61902C2 UA98073527A UA98073527A UA61902C2 UA 61902 C2 UA61902 C2 UA 61902C2 UA 98073527 A UA98073527 A UA 98073527A UA 98073527 A UA98073527 A UA 98073527A UA 61902 C2 UA61902 C2 UA 61902C2
Authority
UA
Ukraine
Prior art keywords
formula
hiv
active ingredient
compounds
virus
Prior art date
Application number
UA98073527A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of UA61902C2 publication Critical patent/UA61902C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
UA98073527A 1995-12-05 1996-05-12 Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition UA61902C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (1)

Publication Number Publication Date
UA61902C2 true UA61902C2 (en) 2003-12-15

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98073527A UA61902C2 (en) 1995-12-05 1996-05-12 Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition

Country Status (23)

Country Link
US (1) US5646180A (cs)
EP (1) EP0866696B1 (cs)
JP (1) JP2000501713A (cs)
KR (1) KR19990071750A (cs)
CN (1) CN1203530A (cs)
AP (1) AP864A (cs)
AT (1) ATE279922T1 (cs)
AU (1) AU722850B2 (cs)
BR (1) BR9611861A (cs)
CA (1) CA2238471A1 (cs)
CZ (1) CZ291994B6 (cs)
DE (1) DE69633680T2 (cs)
ES (1) ES2231828T3 (cs)
HU (1) HUP9903673A3 (cs)
NO (1) NO317837B1 (cs)
NZ (1) NZ324603A (cs)
OA (1) OA10691A (cs)
PL (1) PL187747B1 (cs)
PT (1) PT866696E (cs)
RU (1) RU2203658C2 (cs)
UA (1) UA61902C2 (cs)
WO (1) WO1997020554A1 (cs)
ZA (1) ZA9610139B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
IL127350A0 (en) * 1996-06-25 1999-10-28 Glaxo Group Ltd Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
AU8017298A (en) * 1997-05-17 1998-12-11 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
EP1244670B1 (en) 1999-12-21 2006-03-08 MGI GP, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
DE60133053T2 (de) * 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US20080269161A1 (en) * 2005-01-20 2008-10-30 Seth Perry Compositions and Methods Relating to Mitochondrial Hyperpolarization in Neurological Disease
EP1976976A4 (en) * 2005-12-23 2010-12-15 Univ Rochester TREATMENT OF NEURO-AIDS USING INHIBITORS OF GLYCODY SYNTHASE KINASE (GSK) -3
BRPI0710177A2 (pt) * 2006-04-19 2012-05-29 Abbott Gmbh & Co Kg arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2015131161A2 (en) 2014-02-28 2015-09-03 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2018112229A1 (en) 2016-12-14 2018-06-21 Eam Corporation Absorbent laminates, absorbent cores and disposable articles utilizing the absorbent laminates, and related methods
MX2020012801A (es) 2018-05-28 2021-03-25 Attends Healthcare Products Inc Laminado con capa de sequedad para articulos absorbentes.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
US5646180A (en) 1997-07-08
JP2000501713A (ja) 2000-02-15
DE69633680T2 (de) 2006-02-23
HUP9903673A3 (en) 2000-08-28
ATE279922T1 (de) 2004-11-15
EP0866696A1 (en) 1998-09-30
BR9611861A (pt) 1999-05-18
PT866696E (pt) 2005-03-31
WO1997020554A1 (en) 1997-06-12
AP864A (en) 2000-08-11
CZ291994B6 (cs) 2003-07-16
NO317837B1 (no) 2004-12-20
AP9801340A0 (en) 1998-09-30
CA2238471A1 (en) 1997-06-12
RU2203658C2 (ru) 2003-05-10
HUP9903673A2 (hu) 2000-03-28
NZ324603A (en) 2000-08-25
DE69633680D1 (de) 2004-11-25
AU1148697A (en) 1997-06-27
CZ170898A3 (cs) 1998-09-16
ZA9610139B (en) 1997-06-17
KR19990071750A (ko) 1999-09-27
AU722850B2 (en) 2000-08-10
PL327061A1 (en) 1998-11-23
OA10691A (en) 2001-05-04
PL187747B1 (pl) 2004-09-30
NO982556D0 (no) 1998-06-04
EP0866696B1 (en) 2004-10-20
CN1203530A (zh) 1998-12-30
ES2231828T3 (es) 2005-05-16
NO982556L (no) 1998-06-04

Similar Documents

Publication Publication Date Title
UA61902C2 (en) Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition
JP3046357B2 (ja) アスパルチルプロテアーゼ阻害因子であるｔｈｆ含有スルホンアミド類
KR100485237B1 (ko) 아스파르틸단백분해효소의억제제인산소화된헤테로사이클함유설폰아미드
EP0933372B1 (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
JP2001527062A (ja) アスパルチルプロテアーゼインヒビターのプロドラッグ
WO1999033792A2 (en) Prodrugs os aspartyl protease inhibitors
US20120053139A1 (en) Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
EA011946B1 (ru) Замещённый бензимидазолсульфонамид, ингибитор вич протеазы широкого спектра действия
MXPA00006316A (es) Profarmacos de inhibidores de aspartil proteasa
MXPA97008055A (en) Consistent aspartile protease inhibitors ensulfonamide containing oxygen heterocicle
MXPA00006315A (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors